RXI Pharma (RXII) – FDA
-
RXI Pharma (RXII) Announces Research Collaboration with Karolinska Institutet to Develop d-rxRNA Compounds to Improve Functionality & Persistence of T Cells & NK Cells
-
RXI Pharma (RXII) Reports Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to RXII Stock Lookup